Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Pulse Biosciences, Inc. (PLSE)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
$57.06+9.31%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for PLSE yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Insider buying signals confidence in growth | A supporting condition in Pulse Biosciences, Inc.'s published investment case. The stated target is continued insider confidence through stock purchases. | Intact | no insider buying or insider selling increases | Director bought $13m stock (May 2026) Director Robert W. Duggan acquired $13m in stock on May 15, 2026, signaling strong confidence in growth. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative growth business, with its longer-term case tied to clinical development and the expansion of a controlled commercial launch. The thesis is in a watch state: key study progress is on track, but recent financial performance is weak and the business remains loss-making.
The evidence does not provide a clear valuation level or specific market expectations, so whether PLSE is cheap, fair, or expensive versus peers is unclear. The priced-in fragility assessment is low, but that does not resolve how much confidence the market places in future clinical and commercial progress.
Near term, losses and a run of earnings misses remain concerns; the latest listed miss was in August 2026. Over the multi-year view, enrollment progress in the NANOPULSE-AF study and modestly higher product sales show forward movement, while sector conditions have improved; the evidence does not establish that these gains will produce stronger financial results.
The thesis depends on completing clinical studies and converting clinical progress into meaningful commercial activity. Near term, weaker jobs data could weigh on cyclical healthcare names, while continued strong results from sector bellwethers could support the sector backdrop; misses or lower guidance from those companies could weaken that support.
The 1-to-3-year view remains uncertain: clinical and early commercial progress is encouraging, but losses, weak results, and repeated earnings misses keep execution risk elevated. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in Pulse Biosciences, Inc.'s published investment case. The stated target is stable or improving operational execution in next 4 quarters. |
| Intact |
| no operational improvements or further key departures |
Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Increase revenue through product development | A primary condition in Pulse Biosciences, Inc.'s published investment case. The stated target is >=$400,000 revenue in 2026-Q1. | Intact | revenue falls below $400,000 in 2026-Q1 | Revenue: $434,000 FY2026-Q2; GAAP. Published target: >=$400,000 revenue in 2026-Q1. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 6, 2026434,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.20 → $-1.25 · observed estimates
$0.01B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.20 | $8,866,667 | 2 / 2 |
| 2026-07-25 | $-1.09 | $8,866,670 | 2 / 3 |
| 2026-07-26 | $-1.09 | $8,866,670 | 2 / 3 |
| 2026-07-27 | $-1.09 | $8,866,670 | 2 / 3 |
| 2026-07-28 | $-1.20 | $8,866,667 | 2 / 2 |
| 2026-07-29 | $-1.09 | $8,866,670 | 2 / 3 |
| 2026-07-30 | $-1.20 | $8,866,667 | 2 / 2 |
| 2026-07-31 | $-1.20 | $8,866,667 | 2 / 2 |
| 2026-08-01 | $-1.20 | $8,866,667 | 2 / 2 |
| 2026-08-02 | $-1.09 | $8,866,670 | 2 / 3 |
| 2026-08-03 | $-1.20 | $8,866,667 | 2 / 2 |
| 2026-08-04 | $-1.09 | $8,866,670 | 2 / 3 |
| 2026-08-05 | $-1.09 | $8,866,670 | 2 / 3 |
| 2026-08-06 | $-1.20 | $8,866,667 | 2 / 2 |
| 2026-08-07 | $-1.20 | $8,866,667 | 2 / 2 |
| 2026-08-08 | $-1.09 | $8,866,670 | 2 / 3 |
| 2026-08-09 | $-1.09 | $8,866,670 | 2 / 3 |
| 2026-08-10 | $-1.09 | $8,866,670 | 2 / 3 |
| 2026-08-12 | $-1.16 | $11,400,000 | 2 / 2 |
| 2026-08-13 | $-1.20 | $8,866,667 | 2 / 2 |
| 2026-08-14 | $-1.20 | $8,866,667 | 2 / 2 |
| 2026-08-15 | $-1.20 | $8,866,667 | 2 / 2 |
| 2026-08-16 | $-1.20 | $8,866,667 | 2 / 2 |
| 2026-08-17 | $-1.20 | $8,866,667 | 2 / 2 |
| 2026-08-18 | $-1.20 | $8,866,667 | 2 / 2 |
| 2026-08-19 | $-1.20 | $8,866,667 | 2 / 3 |
| 2026-08-20 | $-1.29 | $7,887,500 | 2 / 3 |
| 2026-08-21 | $-1.29 | $7,887,500 | 2 / 3 |
| 2026-08-22 | $-1.29 | $7,887,500 | 2 / 3 |
| 2026-08-23 | $-1.29 | $7,887,500 | 2 / 3 |
| 2026-08-24 | $-1.29 | $7,887,500 | 2 / 3 |
| 2026-08-25 | $-1.29 | $7,887,500 | 2 / 3 |
| 2026-08-26 | $-1.29 | $7,887,500 | 2 / 3 |
| 2026-08-27 | $-1.29 | $7,887,500 | 2 / 3 |
| 2026-08-28 | $-1.29 | $7,887,500 | 2 / 3 |
| 2026-08-29 | $-1.29 | $7,887,500 | 2 / 3 |
| 2026-08-30 | $-1.29 | $7,887,500 | 2 / 3 |
| 2026-08-31 | $-1.29 | $7,887,500 | 2 / 3 |
| 2026-09-01 | $-1.29 | $7,887,500 | 2 / 3 |
| 2026-09-02 | $-1.29 | $7,887,500 | 2 / 3 |
| 2026-09-03 | $-1.29 | $7,887,500 | 2 / 3 |
| 2026-09-04 | $-1.29 | $7,887,500 | 2 / 3 |
| 2026-09-05 | $-1.29 | $7,887,500 | 2 / 3 |
| 2026-09-06 | $-1.29 | $7,887,500 | 2 / 3 |
| 2026-09-07 | $-1.29 | $7,887,500 | 2 / 3 |
| 2026-09-08 | $-1.29 | $7,887,500 | 2 / 3 |
| 2026-09-09 | $-1.29 | $7,887,500 | 2 / 3 |
| 2026-09-10 | $-1.26 | $7,110,000 | 2 / 3 |
| 2026-09-11 | $-1.26 | $7,110,000 | 2 / 3 |
| 2026-09-12 | $-1.26 | $7,110,000 | 3 / 4 |
| 2026-09-13 | $-1.26 | $7,110,000 | 3 / 4 |
| 2026-09-14 | $-1.26 | $7,110,000 | 3 / 4 |
| 2026-09-15 | $-1.26 | $7,110,000 | 3 / 4 |
| 2026-09-16 | $-1.26 | $7,110,000 | 3 / 4 |
| 2026-09-17 | $-1.26 | $7,110,000 | 3 / 4 |
| 2026-09-18 | $-1.26 | $7,110,000 | 3 / 4 |
| 2026-09-19 | $-1.26 | $7,110,000 | 3 / 4 |
| 2026-09-20 | $-1.26 | $7,110,000 | 3 / 4 |
| 2026-09-21 | $-1.26 | $7,110,000 | 3 / 4 |
| 2026-09-22 | $-1.26 | $7,110,000 | 3 / 4 |
| 2026-09-23 | $-1.26 | $7,110,000 | 3 / 4 |
| 2026-09-24 | $-1.26 | $7,110,000 | 3 / 4 |
| 2026-09-25 | $-1.25 | $6,725,000 | 3 / 4 |
| 2026-09-26 | $-1.25 | $6,725,000 | 3 / 4 |
| 2026-09-27 | $-1.25 | $6,725,000 | 3 / 4 |
| 2026-09-28 | $-1.25 | $6,725,000 | 3 / 4 |
| 2026-09-29 | $-1.25 | $6,725,000 | 3 / 4 |
| 2026-09-30 | $-1.25 | $6,725,000 | 3 / 4 |
| 2026-10-01 | $-1.25 | $6,725,000 | 3 / 4 |
| 2026-10-02 | $-1.25 | $6,725,000 | 3 / 4 |
| 2026-10-03 | $-1.25 | $6,725,000 | 3 / 4 |
| 2026-10-04 | $-1.25 | $6,725,000 | 3 / 4 |
| 2026-10-05 | $-1.25 | $6,725,000 | 3 / 4 |
| 2026-10-06 | $-1.25 | $6,725,000 | 3 / 4 |
| 2026-10-07 | $-1.25 | $6,725,000 | 3 / 4 |
| 2026-10-08 | $-1.25 | $6,725,000 | 3 / 4 |
| 2026-10-09 | $-1.25 | $6,725,000 | 3 / 4 |
| 2026-10-10 | $-1.25 | $6,725,000 | 3 / 4 |
| 2026-10-11 | $-1.25 | $6,725,000 | 3 / 4 |
| 2026-10-12 | $-1.25 | $6,725,000 | 3 / 4 |
| 2026-10-13 | $-1.25 | $6,725,000 | 3 / 4 |
| 2026-10-14 | $-1.25 | $5,641,667 | 3 / 4 |
| 2026-10-15 | $-1.25 | $5,641,667 | 3 / 4 |
| 2026-10-16 | $-1.25 | $5,641,667 | 3 / 4 |
| 2026-10-17 | $-1.25 | $5,641,667 | 3 / 4 |
| 2026-10-18 | $-1.25 | $5,641,667 | 3 / 4 |
| 2026-10-19 | $-1.25 | $5,641,667 | 3 / 4 |
| 2026-10-20 | $-1.25 | $5,641,667 | 3 / 4 |
| 2026-10-21 | $-1.25 | $5,641,667 | 3 / 4 |
| 2026-10-22 | $-1.25 | $5,641,667 | 3 / 4 |
| 2026-10-23 | $-1.25 | $5,641,667 | 3 / 4 |
| 2026-10-24 | $-1.25 | $5,641,667 | 3 / 4 |
| 2026-10-25 | $-1.25 | $5,641,667 | 3 / 4 |
| 2026-10-26 | $-1.25 | $5,641,667 | 3 / 4 |
| 2026-10-27 | $-1.25 | $5,641,667 | 3 / 4 |
| 2026-10-28 | $-1.25 | $5,641,667 | 3 / 4 |
| 2026-10-29 | $-1.25 | $5,641,667 | 3 / 4 |
| 2026-10-30 | $-1.25 | $5,641,667 | 3 / 4 |
| 2026-10-31 | $-1.25 | $5,641,667 | 3 / 4 |
| 2026-11-01 | $-1.25 | $5,641,667 | 3 / 4 |
| 2026-11-02 | $-1.25 | $5,641,667 | 3 / 4 |
| 2026-11-03 | $-1.25 | $5,641,667 | 3 / 4 |
| 2026-11-04 | $-1.25 | $5,641,667 | 3 / 4 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 6 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 2 recorded
3 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.